

December 10, 2020

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Mothers Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8049

## **Solasia's Partner, Isofol Announces Global Phase III AGENT Study Has Recruited 440 Patients**

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announces that 440 patients have been successfully recruited in the global Phase III AGENT study for the treatment of advanced colorectal cancer. For more information, please refer to the following URL link to Isofol's website.

<https://isofolmedical.com/isofol-reaches-440-patients-in-global-phase-iii-agent-study/>

###